NASDAQ · DRMAW
Healthcare · Biotechnology
$0.00
Down-$0.00 (-50.00%)
Updated Sep 13, 2026, 11:41 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 1 trading sessions · Daily adjusted prices
DRMAW closed at $0.00 after 1 trading sessions, up 0.00% for the selected period.
No results
At least two price observations are needed to draw this chart.
The latest Smart Investors Daily articles mentioning DRMAW.
DRMAW research
Company profile and research snapshot.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Nov 14, 2025
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - SAN DIEGO, ...
Benzinga · Jan 4, 2024
Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. What To Know: The announcement of the patent was made Thursday after market close, making it Dermata's first patent issued for DMT410. The program leverages the company's ...Full story available on Benzinga.com
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DRMAW.
No results
No recent SID articles mention DRMAW.
